Restoring Hope for Veterans with Eye Trauma
BVA believes the Department of Defense (DoD) research priority is to “save life, limb, and eyesight,” which has been the motto of military medicine for decades. BVA’s Government Relations team collaborates with policy makers in Congress and the Executive Branch to ensure that service members and veterans impacted by vision loss benefit from sound policies and funding mechanisms focused on military related vision research.
National Eye Institute
No upcoming events.
NEI and the New York Stem Cell Foundation (NYSCF) Research Institute showcase newly available stem cell lines derived from participants in the Age-related Eye Diseases Study 2 and a corresponding clinical database, Tuesday, March 30, 2-3 p.m. ET on Zoom (CLICK HERE). Presenting are Steven Becker, NEI Office of Regenerative Medicine; Kapil Bharti, NEI Ocular and Stem Cell Translational Research Section; Kerry Goetz, NEI Office of Data Science and Health Informatics; and Lauren Bauer, scientific operations and project management, NYSCF. For more information about the webinar (CLICK HERE).
Kevin Chan, NYU Langone, restored optic nerve signals between the brain and eye to near-normal levels in a rat model using citicoline, a major source of choline, a building block in the membranes that line nerve cells and enhance nerve cell communication. While Chan’s research confirmed that elevated eye pressure contributes to nerve damage in glaucoma, it also showed that citicoline reduces vision loss in rats without reducing fluid pressure in the eye. “Our study suggests that citicoline protects against glaucoma through a mechanism different from that of standard treatments that reduce fluid pressure,” he said. To read this NYU Langone news story (CLICK HERE).
Bruce Vogel and colleagues found insights into age-related macular degeneration (AMD) by studying round worms. Several years ago, genomic studies found a link between AMD and the immune protein complement factor H (CFH). But how CFH exerts its effect still isn’t fully understood. “Our findings suggest that complement factor H plays a role in maintaining the organization of photoreceptor cilia, and this process may be defective in AMD,” said Vogel. To read this University of Maryland news story (CLICK HERE).
“In patients who’ve lost their vision from advanced-stage retinal diseases, the artificial retina would mimic the function of photoreceptors…” said Nicole Wagner, chief executive officer of LambdaVision, an NEI small business grantee. LambdaVision is optimizing production of their artificial retina on the International Space Station, where microgravity provides conditions for constructing the multilayered protein-based artificial retina. To read this NEI news story (CLICK HERE).
Gustavo Aguirre and William Beltran, University of Pennsylvania, demonstrated that delivering a normal copy of either the canine or human version of the NPHP5 gene restores vision in dogs with NPHP5 mutations. Similar NPHP5 mutations occur in the human disease Leber congenital amaurosis, where the light-sensing cone photoreceptors fail to develop normally. “What’s amazing is that you can take this disease in which cone cells have incompletely formed, and the therapy restores their function—they had no function whatsoever before—and recover their structure,” said Aguirre. To read this University of Pennsylvania news story (CLICK HERE).
NEI Director Michael F. Chiang issued a statement calling for imaging device makers to standardize their data formatting, joining the American Academy of Ophthalmology and others who say such standardization will enable communication across health care providers, improve quality of care, and enhance the creation of datasets for research. “Not all health care providers speak the same language, but the software in their clinical imaging devices can and should,” Chiang said. To read this NEI statement (CLICK HERE).
Raj Maturi, Indiana University, and the DRCR Retina Network showed that early treatment with anti-VEGF injections slows diabetic retinopathy. However, two years into the four-year study its effect on vision was similar to standard treatment, which usually begins at the onset of late disease. “While it is possible that preventive injections of anti-VEGF drugs may help protect vision in the longer-term, we saw no effect on vision at two years,” said Maturi. To read this NEI news story (CLICK HERE).
Ruchira Singh, University of Rochester, and colleagues developed a living 3D model of the human retina. Their model combines stem cell-derived retinal tissue and vascular networks with bioengineered synthetic materials in a 3D matrix. The researchers are using the model system to investigate the underlying mechanisms of the wet form of age-related macular degeneration. To read this University of Rochester news story (CLICK HERE).
Martin Friedlander, Scripps Research Institute, and collaborators found more than a dozen PHGDH gene variants related to macular telangiectasia type 2 (MacTel), a retinal disease that causes loss of central vision. The PHGDH gene is key to making the amino acid serine. In people with MacTel, low serine levels lead to a build-up of lipids that are toxic to the retina’s light-sensing photoreceptors. To read this Scripps Research news story (CLICK HERE).
NIH-funded study shows early eye injections reduce vision-threatening complications; effect on vision similar to standard treatment. To read this NIH news story (CLICK HERE).
Duygu Kuzum, University of California San Diego, and colleagues developed a device that can run neural network computations using 100 to 1000 times less energy and area than current, state-of-the art CMOS-based hardware. Neural networks comprise connected layers of artificial neurons that can be applied to technology such as automated object recognition in self-driving cars. To read this UC San Diego news story (CLICK HERE).
The National Eye Institute (NEI) Data Commons now enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease Study 2 (AREDS2). The database complements newly available stem cell lines created by the New York Stem Cell Foundation Research Institute (NYSCF) from blood cells of AREDS2 study participants. Together, these resources will accelerate the discovery of therapies for age-related macular degeneration (AMD) and other blinding conditions. The NEI and the NYSCF will host a joint webinar on March 30 to introduce the new NEI AMD Integrative Biology Initiative data portal, housed within the NEI Data Commons.
Johnny Tam and colleagues in the NEI Clinical and Translational Imaging Unit noninvasively visualized light-sensing photoreceptors in greater detail than ever before. The researchers reported in Optica how they improved imaging resolution by a third by selectively blocking the light used to image the eye. To read this NEI news story (CLICK HERE).
Stephen Strittmatter, Yale School of Medicine, and researchers identified 40 genes actively involved in suppression of axon regeneration in central nervous system cells. By editing out one of those genes, they were able to restore axons in ocular nerves of mice damaged by glaucoma. “This opens a new chapter in regeneration research,” said Strittmatter. The research was funded through NEI’s Audacious Goals Initiative. To read this Yale news story (CLICK HERE).
Mary Elizabeth Hartnett, University of Utah, revealed in mouse experiments that an oxidized form of cholesterol called oxysterol 7-ketocholesterol (7KC) can lead to fibrosis (scarring) in the retina. The fibrosis observed by Hartnett is similar to what’s seen in cases of neovascular or ‘wet’ age-related macular degeneration (AMD) that respond poorly to anti-VEGF treatment. “Any time we give anti-VEGF to a patient there can be up to a 50% chance they will ultimately fail treatment…These findings provide a potential explanation for fibrosis and suggest that if we can interfere with this process, we might be able to improve outcomes in many more patients with neovascular AMD,” said Hartnett. To read this UT Health Moran Eye Center news story (CLICK HERE).
Hirofumi Morishita, Mount Sinai, and fellow researchers identified a neural pathway through which the brain detects errors and guides behavioral improvement. This process, called cognitive control, is frequently dysregulated in a range of psychiatric disorders. To read this Mount Sinai news story (CLICK HERE).
Joseph Arboleda-Velasquez and Leo Kim, Harvard, reported that Runt-related transcription factor 1 (RUNX1) inhibition presents a new therapeutic approach in AMD treatment. “RUNX1 inhibitors hold significant promise to complement or replace anti-VEGF therapies for patients in which anti-VEGF therapy is no longer effective, and with the potential to be administered topically it could be transformative in the field,” said Arboleda-Velasquez. To read this Elsevier news story (CLICK HERE).
Janey Wiggs, Harvard University, and an international team of researchers identified 44 new gene loci and confirmed 83 previously reported loci linked to glaucoma. Loci denote locations on a gene. "These new findings come out of the highest-powered genome-wide association study of glaucoma to date, and show the power of team science and using big data to answer questions when research groups around the world join forces," said Wiggs. The findings will help identify new therapeutic targets. To read this Harvard news story (CLICK HERE).
George Church and Constance Cepko, Harvard University, designed a strategy to help gene therapies avoid unwanted stimulation of the immune system. The adeno-associated virus (AAV) has been a leading vehicle for delivery of therapeutic genes because it is non-pathogenic and efficiently targets a variety of cells and tissue types. The researchers modified the AAV genome by adding sequences that inhibit TLR9, a cell receptor involved in inflammation. Importantly, the study highlights that non-TLR9 pathways likely contribute to inflammation in AAV injections in the eye’s gel-like vitreous. To read this Harvard news story (CLICK HERE).
Anna Cliffe, University of Virginia, shed light on the causes of herpes simplex virus (HSV) flare-ups. More than half of Americans are infected with HSV, which lurks inside neurons, waiting for the right moment to reactivate. Recurrent reactivation in the eye leads to herpes keratitis, which, if left untreated, can result in blindness. Cliffe and her collaborators developed an HSV mouse model and found that the virus highjacks an important immune response via the cytokine interleukin beta. To read this University of Virginia news story (CLICK HERE).
Ruchira Singh and colleagues at the University of Rochester discovered that normal CLN3 gene function is crucial for proper function of the retina’s pigmented epithelial cells (RPE). Vision loss is often the first symptom of Batten disease, a rare genetic disorder that also causes learning and behavior problems, slow cognitive decline, seizures, and loss of motor control in children. The researchers’ findings are based on studies of tissues that they re-engineered from Batten disease patients. Understanding how RPE cell dysfunction contributes to photoreceptor cell loss in Batten disease is an important first step, and it will enable researchers to target specific cell type in the eye using potential future gene therapies, cell transplantation, and drug-based interventions, said Singh. To read this University of Rochester news story (CLICK HERE).
Paul Bernstein at the University of Utah Moran Eye Center and colleagues invented a method for synthesizing large quantities of very-long-chain polyunsaturated fatty acids (VLC-PUFAs) to evaluate their potential sight-preserving properties. The study determined that VLC-PUFA supplementation increased levels of the lipids in the retina and also improved visual function in normal mice and in mice with a defect in the ELOVL4 enzyme, which is involved in the body's production of VLC-PUFAs. To read this University of Utah news story (CLICK HERE).
Jayakrishna Ambati, University of Virginia, and colleagues identified a group of drugs that may help stop the dry form of age-related macular degeneration (AMD). The researchers reviewed four different health insurance databases and found that people taking nucleoside reverse transcriptase inhibitors were almost 40% less likely to develop the potentially blinding disease. The researchers think the drug acts by interrupting Alu—RNA fragments that Ambati previously implicated in AMD pathogenesis. “A clinical trial of these inflammasome-inhibiting drugs is now warranted,” he said. To read this University of Virginia Health news story (CLICK HERE).
Thomas Johnson, Johns Hopkins University, and colleagues reported that in mice removing the retina’s internal limiting membrane—a structure that separates retinal neurons from the eye’s gel-like vitreous—facilitates the integration of transplanted retinal ganglion cells (RGCs). The RGCs have long axons that carry visual signals from the eye to the brain. Optic neuropathies such as glaucoma destroy RGCs. “The idea of restoring vision to someone who has lost it from optic nerve disease has been considered science fiction for decades. But in the last five years, stem cell biology has reached a point where it’s feasible,” he said. To read this Hopkins news story (CLICK HERE).
Ting Xie, Stowers Institute, and colleagues found a signaling pathway that affects eye development and maintenance in the ciliary body—a tissue in the eye that controls lens shape and produces aqueous fluid. “The next important question is what other protein factors secreted by the ciliary body are important for maintaining the cornea, the lens, and the retina. Some of these factors could be involved directly in eye diseases,” said Xie. To read this Stowers news story (CLICK HERE).
Aaron Lee, University of Washington School of Medicine, and colleagues found that artificial intelligence algorithms for detecting diabetic retinopathy don’t measure up to their claims. The team deployed 7 algorithm-based technologies on retinal images from nearly 24,000 veterans who sought diabetic retinopathy screening and found that only one matched human screeners. To read this University of Washington news story (CLICK HERE).
George King, Joslin Diabetes Center, showed that routine eye imaging can identify changes in the retina that may be associated with cognitive disorders in older people with type 1 diabetes. King’s team found strong associations between study participants’ performance on memory tasks and structural changes in deep retina blood vessel networks imaged by optical coherence tomography. To read this Joslin news story (CLICK HERE).
Ali Djalilian and Mark Rosenblatt, University of Illinois Chicago, repurposed MEK inhibitors (a class of anti-cancer drugs) to treat an aniridia-like condition in mice. “Patients with aniridia can develop progressive loss of their corneal stem cells…Our research in the Corneal Regenerative Medicine Laboratory is aimed at regenerating healthy corneal cells, which we hope can help these and similar patients,” said Rosenblatt. In the mice, the drug administration enhanced PAX6 gene expression, which normalized eye development and resulted in clearer corneas. To read this University of Illinois Chicago news story (CLICK HERE).
Glenn Yiu, California National Primate Research Center, and colleagues reported that Zika infection during the first trimester of pregnancy can impact retinal development; however, the virus does not appear to affect ocular growth postnatally. The virus is primarily transmitted by the bite of an infected mosquito. However, it can also be passed through sexual contact, blood transfusions, organ transplants, and between mother and baby during pregnancy. “It has been known that congenital infection with the Zika virus can lead to eye defects, but it was unclear if the virus continues to replicate or affect eye development after birth,” Yiu said. “Our study in rhesus monkeys suggests that the virus primarily affects fetal development during pregnancy, but not the growth of the eye after birth,” said Yiu. To read this University of California, Davis news story (CLICK HERE).
Benjamin Scholl, Connon Thomas, and their colleagues at the Max Planck Florida Institute for Neuroscience reported a novel approach to measure the strength of connections between neurons. The team used light microscopy to visualize the activity of a population of synapses and electron microscopy to evaluate structural details of synapses. “Combining both structural and functional measurements of neurons provides a more holistic understanding of how our brains compute information,” said Thomas. To read this Max Planck news story (CLICK HERE).
Derek Welsbie, University of California San Diego, and collaborators identified a family of enzymes whose inhibition protects neurons while also permitting the regeneration of axons—projections that conduct signals between cells. Until now, there have been no effective methods to modify genes to improve both the long-term survival of neurons and promote regeneration. The finding could help efforts to develop therapies for neurodegenerative diseases like Alzheimer’s disease and glaucoma. To read this University of California San Diego story (CLICK HERE).
Shahzad Mian, University of Michigan, and colleagues analyzed the prevalence of COVID-19 in human post-mortem ocular tissues. They found that the virus can infiltrate corneal tissue, raising concerns that the disease could be transmitted to corneal transplant recipients. To read this University of Michigan news story (CLICK HERE).
Adam Glassman (Jaeb Center for Health Research), Jennifer Sun (Harvard University) and fellow researchers with the DRCR Retina Network reported data from a clinical trial that compared anti-vascular endothelial growth factor (VEGF) eye injections versus removal of blood via vitrectomy surgery and laser photocoagulation for proliferative diabetic retinopathy—the growth of new, abnormal blood vessels in the light-sensing retina. Both treatments improved central vision for the majority of participants, although approximately one-third of the participants needed both anti-VEGF injections and surgery. To read this NEI news story (CLICK HERE).
Scott Lambert, Stanford University, and colleagues revealed that children who undergo cataract surgery as infants have a 22% risk of glaucoma 10 years later, whether or not they receive an intraocular lens implant. The findings come from the NEI-funded Infant Aphakic Treatment Study, which published 10-year follow-up results in JAMA Ophthalmology. To read this NEI news story (CLICK HERE).
Richard Krauzlis, senior NEI investigator, and collaborators found that a brain region in the superior temporal sulcus is crucial for processing and making decisions about visual information. The findings, which could provide clues to treating visual conditions from stroke, appear in Neuron. To read this NEI news story (CLICK HERE).
C. Ross Ethier, Georgia Tech, and colleagues have developed a potential glaucoma treatment that could replace daily blood-pressure lowering eye drops and/or surgery. A gel-forming biodegradable polymer is injected just below the eye’s surface to enhance the release of aqueous fluid. According to a report on their research in rabbits, one injection reduced intraocular pressure for 4 months. A challenge to glaucoma treatment is patients forgetting to put drops in their eyes. “We believe the injection could be done as an office procedure during routine exams that the patients are already getting. Patients may not need to do anything to treat their glaucoma until their next office visit,” said Ethier. To read this Georgia Tech news story (CLICK HERE).
Z. Josh Huang, Cold Spring Harbor Laboratory, and colleagues demonstrated the importance of brain-cell pruning to binocular vision. Animals, including humans, kill off brain cells after birth through a pruning process called apoptosis. Based on experiments in mice, Huang reported that preventing apoptosis of chandelier cells in the brain’s visual cortex impairs depth perception. Huang said that reducing chandelier cell number likely frees cells in the binocular region of the visual cortex to communicate more efficiently between the two visual hemispheres, which is essential for rapidly integrating signals relayed from both eyes. To read this Cold Spring harbor Laboratory news story (CLICK HERE).
The mission of the Vision Research Program is to identify and address clinical needs through directed medical research to improve the health and readiness of military personnel affected by eye injuries and vision dysfunction.
To learn more (CLICK HERE).
The mission of the Vision Center of Excellence is to lead and advocate for programs and initiatives with the following three inter-related goals: to improve vision health, optimize readiness, and enhance quality of life for Service members and Veterans.
To learn more (CLICK HERE).
The mission of the National Eye Institute is to conduct and support vision research and education programs that protect and prolong vision.
To learn more (CLICK HERE).
The mission of the Center for the Prevention and Treatment of Visual Loss is to focus on the early detection of potential blinding disorders of the Veteran and general population, including retinal disease, glaucoma, and traumatic brain injury.
To learn more (CLICK HERE).
The mission of the National Alliance for Eye and Vision Research is to achieve the best eye and vision care for all Americans through advocacy and public education for eye and vision research sponsored by the National Institutes of Health (NIH) and its National Eye Institute (NEI), Department of Defense (DoD), Department of Veterans Affairs (VA), and other federal agencies.
To learn more (CLICK HERE).
The mission of the Alliance for Eye and Vision Research is to ensure the best eye and vision care for all Americans through education of congressional legislators, government policymakers, coalition partners, the media and consumers about the value of eye and vision research.
To learn more (CLICK HERE).
The mission of the Association for Research in Vision and Ophthalmology is to advance research worldwide into understanding the visual system and preventing, treating, and curing its disorders.
To learn more (CLICK HERE).
The mission of the National Research and Training Center on Blindness and Low Vision is to enhance employment and independent living outcomes for individuals who are blind or have low vision through research, training, education, and dissemination.
To learn more (CLICK HERE).
The mission of the American Academy of Ophthalmology is to protect sight and empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology.
To learn more (CLICK HERE).
The mission of the American Optometric Association is to advocate for the profession and serve doctors of optometry in meeting the eye care needs of the public.
To learn more (CLICK HERE).
Vets First Podcast
Season 1 Episode 1 - Formation of Vets First Podcast (WEB)
Season 1 Episode 2 - Life After Traumatic Brain Injury (WEB)
Season 1 Episode 3 - Dr. Randy Kardon, VA Center for the Prevention and Treatment of Visual Loss (WEB)
Season 1 Episode 4 - Out of the Dark and Into the Light: Life After Successful Treatment of Post-Traumatic Headache (WEB)
Season 1 Episode 5 - When Our Blood Filtration System Goes Bad: Two Veteran Viewpoints on Kidney Disease (WEB)
Season 1 Episode 6 - Extraordinary Circumstances: Son Donates Kidney to Father and Jack Jones Receives the First Hepatitis C Positive Kidney (WEB)
Season 1 Episode 7 - Pioneer in Kidney Transplant: Dr. Christie Thomas (WEB)
Season 1 Episode 8 - Season One in the Books (WEB)
Check out the NRTC's Spring 2021 newsletter for the latest research highlights and new resources. (CLICK HERE).
The NRTC is recruiting participants for a new study about Access Technology (AT) use in the workplace! If you are blind or have low vision, use AT, and are working or interested in working, you may qualify for the study. For more information (CLICK HERE).
We updated our Supplemental Security Income (SSI) fact sheets for youth with visual impairments who receive SSI benefits and their parents. The fact sheets provide general information about several SSI work incentives, examples of calculations, and links to more detailed information. You can find them on our website for free (CLICK HERE).
The NRTC has two new free courses developed by IL OIB-TAC:
How Social Determinants of Health Relate to Vision and Aging: In this course, Dr. Pricilla Rogers looks at how social determinants impact the prevalence of vision loss. Discussion focuses on how individuals with vision impairment or blindness are at greater risk for additional health impairments and considers strategies for how service providers can ease the effects of social determinants (1-hour CRC, ACVREP, and NBPCB) To view the course (CLICK HERE).
Fall Prevention: Interventions for Older Individuals who are Visually Impaired: In this course, learn how to identify individuals at risk for falls, review home safety checklists, and examine strategies to prevent falls (1-hour CRC, ACVREP, and NBPCB) To view the course (CLICK HERE).
The IL OIB-TAC has updated its Lessons for Living Series, which provides an overview of adaptive strategies and techniques to help one adjust to vision loss. This tool for professionals and individuals experiencing vision loss is currently available as downloadable Word files and will be available as audio files later this year. To view this series (CLICK HERE).
Please save the date for the IL OIB-TAC March webinar with the Department of Veterans Affairs on Friday, March 19 at 2:00 PM (CST). Join us to learn more about the programs and services available in 2021. Registration is required. For more information and to register, (CLICK HERE) to visit our Community of Practice event page.